New Biological Insights and Recent Therapeutic Advances in the Management of Acute and Chronic Leukemias and Myelodysplastic Syndromes

A Clinical Investigator Think Tank

CME Information

TARGET AUDIENCE

This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY

Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders (eg, myelodysplastic syndromes [MDS], myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 162,020 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2015 and 56,630 individuals will die from these diseases. Importantly, more than 60 drug products are currently labeled for use in the management of hematologic cancers, and although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

By reviewing the available clinical trial data and relevant case scenarios, this initiative will provide insight into the gaps in medical knowledge and illuminate treatment ambiguities pertinent to the management of acute and chronic leukemias and MDS. To address these issues, this CME program brings together leading clinical investigators to provide biological insights into the recent therapeutic advances in the management of these cancers.

LEARNING OBJECTIVES

- Appraise recent data on therapeutic advances and changing practice standards in the management of select acute and chronic leukemias and MDS, and refine or validate existing treatment algorithms based on discussion of this information.
- Appreciate the FDA approvals of novel targeted agents indicated for the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia, and discern how these treatments can be appropriately integrated into clinical practice.
- Recognize evidence-based therapeutic options for patients with progressive chronic myeloid leukemia.
- Review existing and evolving clinical trial data to recommend safe therapeutic alternatives for patients with acute myeloid leukemia, including acute promyelocytic leukemia, and increase knowledge regarding investigational options designed for patients who are not candidates for intensive therapy.
- Apply the results of emerging clinical research to optimize treatment for young adult and adult patients with newly diagnosed and recurrent acute lymphoblastic leukemia.
- Counsel patients with MDS about supportive and systemic treatment options to manage disease-related cytopenias and minimize leukemic progression.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/LeukemiaTT115/Video/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Jennifer R Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School-
Boston, Massachusetts

Advisory Committee: Celgene Corporation, Emergent BioSolutions Inc, Gilead Sciences Inc, Janssen Biotech Inc, MorphoSys, Pharmacyclics Inc, ProNAi Therapeutics Inc; **Consulting Agreements:** Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Emergent BioSolutions Inc, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, MorphoSys, Pharmacyclics Inc, ProNAi Therapeutics Inc, Roche Laboratories Inc.

Hagop M Kantarjian, MD
Chairman and Professor, Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

No real or apparent conflicts of interest to disclose.

Charles A Schiffer, MD
Professor of Medicine and Oncology
Joseph Dresner Chair for Hematologic Malignancies
Chief, Multidisciplinary Leukemia/Lymphoma Group
Wayne State University School of Medicine
Karmanos Cancer Institute
Detroit, Michigan

Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Novartis Pharmaceuticals Corporation, Takeda Oncology; **Consulting Agreement:** Celgene Corporation; **Contracted Research:** Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Takeda Oncology; **Research Support:** MedImmune Inc; **Other Remunerated Activities:** Pfizer Inc, Takeda Oncology.

B Douglas Smith, MD
Associate Professor of Oncology
Division of Hematologic Malignancies
The Sidney Kimmel Comprehensive Cancer Center
at Johns Hopkins
Baltimore, Maryland

Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc.

David P Steensma, MD
Faculty Member, Adult Leukemia Program
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: Amgen Inc, Celgene Corporation, Genoptix Inc.

Wendy Stock, MD, MA
Professor of Medicine
University of Chicago
Director, Leukemia Program
Chicago, Illinois

Advisory Committee: Amgen Inc, Gilead Sciences Inc, Sigma-Tau Pharmaceuticals Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation and Teva Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: August 2015

Expiration date: August 2016

Select Publications

Aldoss I et al. **The toxicity profile of repeated doses of peg-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.** *Eur J Haematol* 2015;[Epub ahead of print].

Bigliardi S et al. **Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: A retrospective monocenter study.** *Leuk Lymphoma* 2014;[Epub ahead of print].

Cortes J et al. **Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase trial (DASISION, CA180-056).** *Proc ASH* 2014;Abstract 152.

Cortes JE et al. **Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.** *Cancer* 2015;121(10):1637-44.

DeAngelo DJ et al. **Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.** *Leukemia* 2014;29(3):526-34.

Döhner H et al. **Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.** *Blood* 2014;124(9):1426-33.

Flinn I et al. **Preliminary results of a Phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia.** *Proc ASH* 2014;**Abstract 4687**.

Freeman C et al. **Risk factors associated with the development of infusion-related reactions in patients with chronic lymphocytic leukaemia treated with anti-CD20 monoclonal antibodies: Analysis of the CLL11 study dataset.** *Proc ASH* 2014;**Abstract 3339**.

Goede V et al. **Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study.** *Leukemia* 2015;29(7):1602-4.

Goede V et al. **Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.** *N Engl J Med* 2014;370(12):1101-10.

Goede V et al. **Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia and comorbidities: Results of the CLL11 study.** *Proc ASH* 2014;**Abstract 3327**.

Greil R et al. **Rituximab maintenance after chemoimmunotherapy induction in 1st and 2nd line improves progression free survival: Planned interim analysis of the international randomized AGMTCLL8/a Mabtenance trial.** *Proc ASH* 2014;**Abstract 20**.

Grupp SA et al. **T cells engineered with a chimeric antigen receptor targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL.** *Proc ASH* 2014;**Abstract 380**.

Mahon FX et al. **Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: The EURO-SKI study.** *Proc ASH* 2014;**Abstract 151**.

O'Brien S et al. **Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: Results from the phase II RESONATE™-17 trial.** *Proc ASH* 2014;**Abstract 327**.

O'Brien SG et al. **Spirit 2: An NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML.** *Proc ASH* 2014;**Abstract 517**.

Park JH et al. **CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL.** *Proc ASH* 2014;**Abstract 382**.

Platzbecker U et al. **Improved outcome with ATRA-arsenic trioxide compared to ATRA-chemotherapy in non-high risk acute promyelocytic leukemia — Updated results of the Italian-German APL0406 trial on the extended final series.** *Proc ASH* 2014;**Abstract 12**.

Rea D et al. **Dasatinib or nilotinib discontinuation in chronic phase-chronic myeloid leukemia patients with durably undetectable BCRABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months — On behalf of the French CML Group Filmc.** *Proc ASH* 2014;**Abstract 811**.

Roberts A et al. **Determination of recommended Phase 2 dose of ABT-199 (GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia.** *Proc ASH* 2014;**Abstract 325**.

Röllig C et al. **Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: Results from 267 patients treated in the randomized placebo-controlled SAL-Soraml trial.** *Proc ASH* 2014;**Abstract 6**.

Select Publications

Rousselot P et al. **Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.** *J Clin Oncol* 2014;32(5):424-30.

Santini V et al. **Efficacy and safety of lenalidomide versus placebo in RBC-transfusion dependent patients with IPSS low/intermediate (int-1)-risk myelodysplastic syndromes without del(5q) and unresponsive or refractory to erythropoiesis-stimulating agents: Results from a randomized phase 3 study (CC-5013-MDS-005).** *Proc ASH* 2014;**Abstract 409**.

Seymour JF et al. **International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.** *Blood* 2015;126(3):291-9.

Sharman J et al. **Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab for relapsed chronic lymphocytic leukemia: Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors.** *Proc ASH* 2014;**Abstract 330**.

Stock W et al. **Favorable outcomes for older adolescents and young adults with acute lymphoblastic leukemia: Early results of US Intergroup trial C10403.** *Proc ASH* 2014;**Abstract 796**.

Topp MS et al. **Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study.** *Lancet Oncol* 2015;16(1):57-66.

van Oers MHJ et al. **Ofatumumab maintenance prolongs PFS in relapsed CLL: Prolong study interim analysis results.** *Proc ASH* 2014;**Abstract 21**.